Fullerton Health Announces a Significant Investment from Ping An Capital

Food and Healthcare Press Releases Tuesday November 28, 2017 08:30
SHANGHAI--28 Nov--PRNewswire/InfoQuest

Fullerton Healthcare Corporation Limited ("Fullerton Health" or the "Group"), a leading provider of corporate healthcare solutions across Asia Pacific, today announced a significant investment from Ping An Capital Co., Ltd. ("Ping An Capital"), the core equity investment platform of Ping An Insurance (Group) Company of China, Ltd ("Ping An of China").

To provide more affordable and accessible healthcare to its people, China has been reforming its healthcare system, starting with increasing medical spending, building capacity at the grassroots level and gradually increasing focus on supply side reform, reducing costs and improving efficiency.

David Sin, Deputy Chairman, Fullerton Health commented: "This partnership is an important milestone for Fullerton Health in China. Together with its related parties, the investment team of Ping An Capital led an investment of more than RMB 800 million into Fullerton, further cementing our relationship with Ping An of China. With the investment, Ping An Capital and its related parties have become Fullerton's second largest shareholder. The partnership offers a broad platform for Fullerton Health to expand our presence in the growing Chinese enterprise healthcare market."

Dr. Michael Tan, Co-Founder and Group CEO of Fullerton Health commented: "With the deepening of China's healthcare reform, there is no better time for Fullerton Health to expand into the Chinese market. As a leading provider of corporate healthcare solutions in the Asia Pacific region with a proven track record, Fullerton Health is uniquely positioned to offer quality healthcare that is affordable and accessible in China. Working closely with our China partners, we look forward to using our expertise to meet the ever-increasing demands of the Chinese healthcare market."

Although China's private healthcare market is still in its early stages of development, it has great potential due to the country's rapid economic growth, favourable demographic changes, and low penetration rate of the existing enterprise healthcare service market. According to a 2016 Frost & Sullivan research report, China's market for enterprise healthcare management will grow from $5.7 billion in 2010 to $21.1 billion in 2020.

Fullerton Health focuses on delivering enterprise healthcare services and currently serves over 25,000 companies. As a first step for its mainland China operations, Fullerton Health plans to establish approximately 100 clinics in major cities of Beijing, Shanghai and Guangzhou.

Liu Dong, Principal Partner of Ping An Capital commented, "Fullerton Health provides comprehensive medical services across five countries and regions in the Asia Pacific region. As Ping An of China's core equity investment platform, Ping An Capital's investment into Fullerton Health paves the way for Fullerton Health to adapt its well-established business model in mainland China. In addition to capital investment, Ping An Capital will leverage healthcare resources from Ping An of China, including Ping An health insurance, Ping An Good Doctor and Ping An Wanjia Healthcare to help boost Fullerton Health's business expansion in mainland China."

Ping An Insurance (Group) Company of China, Ltd., the controlling shareholder of Ping An Capital, became the world's largest insurer by market value in 2017. In the first half of 2017, Ping An's life and health insurance new business value reached nearly RMB38.5 billion, a robust growth of 46.2% year-on-year. The company has also been making consistent investments in the healthcare sector. Via the online "Ping An Good Doctor" health management platform and the offline "Ping An Wanjia Healthcare" health service chain, Ping An has connected hospitals, clinics, doctors, drug stores, check-up centers and other medical institutions to provide patients with comprehensive healthcare services. As of May 2017, Ping An Good Doctor provided health management services to 160 million Chinese users.

Media Contact:
Brunswick Group
Will Carnwath
Ben Fry
FullertonHealth@brunswickgroup.com
+65-6426-8188

Latest Press Release

Whisk#s AI-Powered Culinary Coach Named as Winner of Ascensia Diabetes Challenge

Today, at the American Diabetes Association's 78th Scientific Sessions in Orlando, Florida, Ascensia Diabetes Care has revealed that UK-based Whisk have been selected as the winner of the Ascensia Diabetes Challenge, a global innovation competition that...

Significant Blood Sugar Improvement With Xultophy(R) Compared to Insulin Glargine U-100 When Used as Add-On to Oral Diabetes Medications

Adults with type 2 diabetes treated with Xultophy(R) (insulin degludec and liraglutide injection) also experienced no change in body weight, lower rates of hypoglycaemia and a lower insulin dose at 26 weeks Xultophy(R) (insulin degludec and liraglutide...

Tresiba(R) Demonstrated Significantly Improved Blood Sugar Control and Lower Rates of Hypoglycaemia Versus Insulin Glargine U300 in Real-World Evidence Study

Adults with type 2 diabetes treated with Tresiba(R) (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin Findings from CONFIRM - a large real-world evidence (RWE)...

Ozempic(R) Provided Greater Weight Reductions for Adults With a Baseline BMI ?25kg/m2 Than Those With Lower Baseline BMI 25kg/m2, in a SUSTAIN 7 Post-hoc Analysis

Ozempic(R) (semaglutide) 0.5 mg or 1.0 mg provided greater weight reductions vs dulaglutide 0.75 mg or 1.5 mg, respectively, in adults with type 2 diabetes, regardless of baseline body mass index (BMI), with the greatest reductions occurring in adults...

Oral Semaglutide Demonstrated Significant Reduction in Blood Sugar vs Placebo in PIONEER 1 Trial

Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type 2 diabetes, according to findings from the PIONEER 1 phase 3a trial. The trial evaluated...

Related Topics